In vitro and in vivo therapeutic efficacy of CXCR 4 antagonist BKT 140 against human non – small cell lung cancer

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Unknown venue

• Publication date

  Unknown publication date

• Fields of study

  Not labeled

• Identifiers

  No identifiers available.

• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Upregulation of CXCR4 is functionally crucial for maintenance of stemness in drug-resistant non-small cell lung cancer cells

  2013cited by this paper
• The chemokine system and cancer

  2012influential reference
• Five-year survival does not equal cure in non-small cell lung cancer: a Surveillance, Epidemiology, and End Results-based analysis of variables affecting 10- to 18-year survival.

  2012cited by this paper
• Development of novel CXCR4-based therapeutics

  2012influential reference
• Potential of CXCR4 antagonists for the treatment of metastatic lung cancer

  2011influential reference
• Interaction between neoplastic cells and cancer-associated fibroblasts through the CXCL12/CXCR4 axis: role in non-small cell lung cancer tumor proliferation.

  2011cited by this paper
• Chemotherapy, chemoresistance and the changing treatment landscape for NSCLC.

  2011influential reference
• Homeostatic chemokine receptors and organ-specific metastasis

  2011cited by this paper
• Concise Review: Emerging Concepts in Clinical Targeting of Cancer Stem Cells

  2011cited by this paper
• Involvement of CCR6/CCL20/IL-17 Axis in NSCLC Disease Progression

  2011cited by this paper
• PET imaging of CXCR4 using copper-64 labeled peptide antagonist

  2011cited by this paper
• CXCR4 antagonist 4F-benzoyl-TN14003 inhibits leukemia and multiple myeloma tumor growth.

  2011cited by this paper
• Cell of origin of lung cancer

  2010cited by this paper
• Lung Cancer Stem Cell: New Insights on Experimental Models and Preclinical Data

  2010cited by this paper
• PET of Tumor CXCR4 Expression with 4-18F-T140

  2010cited by this paper
• Cancer Statistics, 2010

  2010cited by this paper
• Highly tumorigenic lung cancer CD133+ cells display stem-like features and are spared by cisplatin treatment

  2009cited by this paper
• CXCL12 and CXCR4 in adenocarcinoma of the lung: association with metastasis and survival.

  2009cited by this paper
• The CXCR4 antagonist 4F-benzoyl-TN14003 stimulates the recovery of the bone marrow after transplantation

  2009influential reference
• Interaction between CXCR4 and CCL20 Pathways Regulates Tumor Growth

  2009cited by this paper
• CXCR4 antagonists: targeting the microenvironment in leukemia and other cancers

  2009cited by this paper
• Identification and expansion of the tumorigenic lung cancer stem cell population

  2008cited by this paper
• Enhanced Unique Pattern of Hematopoietic Cell Mobilization Induced by the CXCR4 Antagonist 4F‐Benzoyl‐TN14003

  2007influential reference
• CD4+CXCR4highCD69+ T Cells Accumulate in Lung Adenocarcinoma

  2006cited by this paper
• CXCR4: a key receptor in the crosstalk between tumor cells and their microenvironment.

  2006cited by this paper
• Differential Expression of CXCR4 Is Associated with the Metastatic Potential of Human Non–Small Cell Lung Cancer Cells

  2005cited by this paper
• Chemokines in neoplastic progression.

  2004cited by this paper
• Chemokine receptor CXCR4 and early-stage non-small cell lung cancer: pattern of expression and correlation with outcome.

  2004cited by this paper
• The therapeutic potential of CXCR4 antagonists in the treatment of HIV

  2003cited by this paper
• The stromal derived factor-1/CXCL12-CXC chemokine receptor 4 biological axis in non-small cell lung cancer metastases.

  2003cited by this paper
• A low-molecular-weight inhibitor against the chemokine receptor CXCR4: a strong anti-HIV peptide T140.

  1998cited by this paper

• LFC131 peptide-conjugated polymeric nanoparticles for the effective delivery of docetaxel in CXCR4 overexpressed lung cancer cells.

  2015cites this paper
• a meta-analysis for cXcr 4 as a prognostic marker and potential drug target in non-small cell lung cancer

  2015cites this paper
• CXC and CC Chemokines as Angiogenic Modulators in Nonhaematological Tumors

  2014cites this paper